M
MLTX
MoonLake Immunotherapeutics
18.19
-0.28-1.52%After Hours: 18.10 -0.09 -0.49%19:37 05/22 EDT
OPEN/PREV CLOSE18.50/18.47
TODAY RANGE18.00-18.75
VOL653.76K
MARKET CAP1.34B
52 WEEK RANGE5.95-62.75
AVG VOL (3M)1.03M
% TURNOVER0.89%
TURNOVER--
P/E (TTM)-4.7010
% RANGE4.06%
EPS(TTM)-3.8694
P/E(FORWARD)-4.5934
P/B5.17
BVPS3.522
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.21B
SHARES OUTSTANDING73.62M
NEXT EARNINGS08/03-08/07
FREE FLOAT66.51M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·05/12 11:31
MoonLake Immunotherap Price Target Raised to $30.00/Share From $25.00 by Needham
Dow Jones·05/12 11:31
MoonLake Immunotherap Is Maintained at Buy by Needham
Benzinga·05/12 11:21
Needham Maintains Buy on MoonLake, Raises Price Target to $30
TipRanks·05/12 11:16
Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)
Benzinga·05/11 15:44
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
PUBT·05/11 12:56
MoonLake Q1 net loss widens 71.9% to $69.7 million
TipRanks·05/11 12:01
Goldman Sachs Keeps Their Sell Rating on MoonLake Immunotherapeutics (MLTX)
TipRanks·05/11 11:31
MoonLake advances sonelokimab toward BLA after positive FDA meeting